Today, Alladapt announced the appointment of Louise Peacock as Chief Regulatory Affairs and Quality Officer. Louise has more than three decades of experience in drug development & regulatory approvals & we are excited to have her join our team. Learn more: assets.website-files.com/5e4aeee404e0b8…

We’re joining FARE (@foodallergy) during #foodallergyawarenessweek to raise awareness of #FA. Today, we honor health care providers who make a difference in the FA community. The work they do is invaluable in the lives of food allergy patients, family, friends & caregivers. #FAAW

Alladapt’s Co-founder Dr. Kari Nadeau spoke with The @Guardian about #foodallergy around the world, the rise of #foodallergies and what a possible cure could look like. Listen here: theguardian.com/science/audio/…

Tomorrow, our CFO Glenn Reicin will present the Alladapt story at the Jefferies Healthcare conference in New York City.

Our clinical team is in Germany at the prestigious EAACI Congress 2023, where our #clinicalstudy investigators will review topline results from our Phase 1/2 Harmony Trial evaluating ADP101 for the treatment of mono or multi #foodallergy. #EAACI2023 lnkd.in/ewJK_9Qm

Tomorrow morning, Dr. Shaila Gogate from Colorado Allergy & Asthma Centers - Denver and CU School of Medicine will give a flash talk on baseline characteristics from Alladapt’s Phase 1/2 Harmony Trial. #EAACI2023. More details here: eaaci.org/events_congres…

Today, Alladapt announced topline data from our Phase 1/2 Harmony Study evaluating ADP101 for the treatment of patients with mono- and multi- #FoodAllergy, as presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress. #EAACI2023 assets.website-files.com/5e4aeee404e0b8…

Alladapt CEO Ashley Dombkowski speaks to us about promising early trial results in kids with the multi-allergy OIT formula ADP101. (Developed by Dr. Kari Nadeau.) "We saw people desensitizing to more than one allergen at a time." Alladapt Immunotherapeutics Brian Schroer MD #foodallergies

Alladapt’s Co-founder and CEO Ashley Dombkowski spoke with Allergic Living recently about Alladapt’s promising P1/2 clinical data in #foodallergy. allergicliving.com/2023/06/29/oit…

Three teenagers take action and get a law passed. Meanwhile, hundreds of thousands of adults working in biotech count on someone else to shape policy. Thank you to those who stand… 1/14

Eating out with #foodallergies can be stressful, but don’t be afraid to speak up for yourself when it comes to food safety and your #foodallergy.

#ICYMI: Last month, Alladapt announced topline pediatric data from our Phase 1/2 Harmony Study evaluating ADP101 for the treatment of patients with mono- and multi-Food Allergy. #FoodAllergy Learn more: lnkd.in/egiK7GFS

At Alladapt, we’re driven by our five core values, each of which motivate the Alladapt team to work together to improve the lives of those impacted by #foodallergy. Learn more about them: alladapt.com/#our-values

CFAAR's Dr. Ruchi Gupta and Dr. Chris Warren were co-authors in Dr. Kari Nadeau’s article, “Food allergy risks and dining industry – an assessment and a path forward.” Patients with #food allergies understand the challenges of dining out. Read more: bit.ly/3OHF2Wn

Today, we're participating in the I&I panel at Citi’s #BioPharma Conference in Boston. Food allergy affects 32m in the US alone; 95% lack treatments. Rapid clinical advances in #immunology are poised to change this. View the webcast: veracast.com/webcasts/citig…

Our CEO Ashley Dombkowski will be speaking alongside other life science leaders this Friday at the Biocom California CEO Summit. We look forward to connecting with our peers and discussing Alladapt's mission to help people with #FoodAllergies worldwide. #BiocomCEOSummit

Lake Travis HS teenager with #peanutallergy exposed to peanuts on purpose by high school football teammates.When we talk about the jokes about #foodallergies leading to IRL consequences this is a case in point. cbsaustin.com/news/local/lak… They spread peanut powder /peanut products

We're grateful for the opportunity to share promising results with the food allergy community at #ACAAI23! #ICYMI, read highlights from our Phase 1/2 Harmony Study evaluating ADP101 for the treatment of patients with mono- and multi- #FoodAllergy here: bit.ly/49rPSIh

ADP101 has received Fast Track designation from the FDA, marking an important milestone for people suffering from #FoodAllergy. We'll continue to work closely with the FDA to expedite development of this important therapy. Learn more in our press release: bit.ly/482MoL1

More exciting news on the treatment front as Alladapt Immunotherapeutics receives FDA Fast Track designation for its OIT treatment that tackles #foodallergies to all Top 9 at the same time. snacksafely.com/2023/11/fda-fa…